What is a stock summary page? Click here for an overview.
Business Description
Alivus Life Sciences Ltd
ISIN : INE03Q201024
Compare
Compare
Traded in other countries / regions
543322.India Index Membership
NIFTY 500NIFTY 500 IPO Date
2021-08-06Description
Alivus Life Sciences Ltd, formerly Glenmark Life Sciences Ltd develops, manufactures, and supplies high-quality active pharmaceutical ingredients for cardiovascular disease, central nervous system disease, pain management, diabetes, gastrointestinal disorders, anti-infectives, and other therapeutic areas.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 33.19 | |||||
| Equity-to-Asset | 0.82 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | 0.02 | |||||
| Interest Coverage | 374.02 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 15.46 | |||||
| Beneish M-Score | -2.39 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 5.4 | |||||
| 3-Year EBITDA Growth Rate | 5 | |||||
| 3-Year EPS without NRI Growth Rate | 10.2 | |||||
| 3-Year FCF Growth Rate | -3.9 | |||||
| 3-Year Book Growth Rate | 45.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 14.62 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 13.88 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 34.72 | |||||
| 9-Day RSI | 41.96 | |||||
| 14-Day RSI | 44.86 | |||||
| 3-1 Month Momentum % | -0.96 | |||||
| 6-1 Month Momentum % | -11.31 | |||||
| 12-1 Month Momentum % | 25.27 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.52 | |||||
| Quick Ratio | 3.03 | |||||
| Cash Ratio | 1.14 | |||||
| Days Inventory | 233.42 | |||||
| Days Sales Outstanding | 131.32 | |||||
| Days Payable | 132.78 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | 0.02 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 51.48 | |||||
| Operating Margin % | 26.1 | |||||
| Net Margin % | 20.3 | |||||
| FCF Margin % | 13.08 | |||||
| ROE % | 18.25 | |||||
| ROA % | 14.91 | |||||
| ROIC % | 20.1 | |||||
| 3-Year ROIIC % | 3.09 | |||||
| ROC (Joel Greenblatt) % | 29.94 | |||||
| ROCE % | 23.8 | |||||
| Years of Profitability over Past 10-Year | 6 |
GF Value Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 27.88 | |||||
| Forward PE Ratio | 20.51 | |||||
| PE Ratio without NRI | 27.88 | |||||
| Price-to-Owner-Earnings | 38.68 | |||||
| PEG Ratio | 2.71 | |||||
| PS Ratio | 5.66 | |||||
| PB Ratio | 4.84 | |||||
| Price-to-Tangible-Book | 4.87 | |||||
| Price-to-Free-Cash-Flow | 43.2 | |||||
| Price-to-Operating-Cash-Flow | 29.72 | |||||
| EV-to-EBIT | 19.8 | |||||
| EV-to-Forward-EBIT | 14.78 | |||||
| EV-to-EBITDA | 18.01 | |||||
| EV-to-Forward-EBITDA | 13.63 | |||||
| EV-to-Revenue | 5.41 | |||||
| EV-to-Forward-Revenue | 4.22 | |||||
| EV-to-FCF | 41.34 | |||||
| Price-to-GF-Value | 1.4 | |||||
| Price-to-Peter-Lynch-Fair-Value | 2.54 | |||||
| Price-to-Graham-Number | 2.51 | |||||
| Price-to-Net-Current-Asset-Value | 7.92 | |||||
| Earnings Yield (Greenblatt) % | 5.05 | |||||
| FCF Yield % | 2.32 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Alivus Life Sciences Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 21,754.92 | ||
| EPS (TTM) (₹) | 35.93 | ||
| Beta | 0.94 | ||
| 3-Year Sharpe Ratio | 0.72 | ||
| 3-Year Sortino Ratio | 1.36 | ||
| Volatility % | 44.05 | ||
| 14-Day RSI | 44.86 | ||
| 14-Day ATR (₹) | 59.043183 | ||
| 20-Day SMA (₹) | 1046.155 | ||
| 12-1 Month Momentum % | 25.27 | ||
| 52-Week Range (₹) | 743.85 - 1335.1 | ||
| Shares Outstanding (Mil) | 122.54 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Alivus Life Sciences Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Alivus Life Sciences Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| No Event Data | ||||
Alivus Life Sciences Ltd Frequently Asked Questions
What is Alivus Life Sciences Ltd(NSE:ALIVUS)'s stock price today?
The current price of NSE:ALIVUS is ₹1001.05. The 52 week high of NSE:ALIVUS is ₹1335.10 and 52 week low is ₹743.85.
When is next earnings date of Alivus Life Sciences Ltd(NSE:ALIVUS)?
The next earnings date of Alivus Life Sciences Ltd(NSE:ALIVUS) is 2025-04-25 Est..
Does Alivus Life Sciences Ltd(NSE:ALIVUS) pay dividends? If so, how much?
Alivus Life Sciences Ltd(NSE:ALIVUS) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers